Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
January 8, 2026 4:05 PM ESTMr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions
DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026.
Mr. Riga joined Jazz in April 2025 through the acquisition... More
